Table of Contents
ISRN Otolaryngology
Volume 2011, Article ID 931813, 8 pages
http://dx.doi.org/10.5402/2011/931813
Review Article

The Role of p53 and MDM2 in Head and Neck Cancer

1Oncology Department, ASO Santa Croce e Carle Cuneo, Via Michele Coppino 21, 12100 Cuneo, Italy
2Radiotherapy Department, ASO Santa Croce e Carle Cuneo, Via Michele Coppino 21, 12100 Cuneo, Italy
3Oncology Department, Policlinico G Martino, Via Consolare Valeria 1, 98100 Messina, Italy

Received 6 September 2011; Accepted 29 September 2011

Academic Editors: K. Ishikawa and M. Khyatti

Copyright © 2011 N. Denaro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Argiris, M. V. Karamouzis, D. Raben, and R. L. Ferris, “Head and neck cancer,” The Lancet, vol. 371, no. 9625, pp. 1695–1709, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Lothaire, E. A. D. Dequanter, Y. Lalami et al., “Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation,” Head and Neck, vol. 28, no. 3, pp. 256–269, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. B. Perez-Ordoñez, M. Beauchemin, and R. C. K. Jordan, “Molecular biology of squamous cell carcinoma of the head and neck,” Journal of Clinical Pathology, vol. 59, no. 5, pp. 445–453, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. Y. Oh and L. Mao, “Biomarkers in head and neck carcinoma,” Current Opinion in Oncology, vol. 9, no. 3, pp. 247–256, 1997. View at Google Scholar · View at Scopus
  5. D. Bergamaschi, M. Gasco, L. Hiller et al., “p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis,” Cancer Cell, vol. 3, no. 4, pp. 387–402, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Cahilly-Snyder, T. Yang-Feng, U. Francke, and D. L. George, “Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line,” Somatic Cell and Molecular Genetics, vol. 13, no. 3, pp. 235–244, 1987. View at Publisher · View at Google Scholar · View at Scopus
  7. Z. Wang and B. Li, “Mdm2 links genotoxic stress and metabolism to p53,” Protein and Cell, vol. 1, no. 12, pp. 1063–1072, 2010. View at Publisher · View at Google Scholar
  8. S. Shangary and S. Wang, “Targeting the MDM2-p53 interaction for cancer therapy,” Clinical Cancer Research, vol. 14, no. 17, pp. 5318–5324, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. S. F. Huang, I. H. Chen, C. T. Liao, H. M. Wang, S. H. Liou, and L. L. Hsieh, “Combined effects of MDM2 SNP 309 and p53 mutation on oral squamous cell carcinomas associated with areca quid chewing,” Oral Oncology, vol. 45, no. 1, pp. 16–22, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Nenutil, J. Smardova, S. Pavlova et al., “Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry,” Journal of Pathology, vol. 207, no. 3, pp. 251–259, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. X. Wang, J. Wang, and X. Jiang, “MdmX protein is essential for Mdm2 protein-mediated p53 polyubiquitination,” Journal of Biological Chemistry, vol. 286, no. 27, pp. 23725–23734, 2011. View at Publisher · View at Google Scholar
  12. Y. A. Valentin-Vega, J. A. Barboza, G. P. Chau, A. K. El-Naggar, and G. Lozano, “High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas,” Human Pathology, vol. 38, no. 10, pp. 1553–1562, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. X. L. Zhuo, Q. Li, Y. Zhou et al., “Study on TP53 codon 72 polymorphisms with oral carcinoma susceptibility,” Archives of Medical Research, vol. 40, no. 7, pp. 625–634, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Alhopuro, S. K. Ylisaukko-Oja, W. J. Koskinen et al., “The MDM2 promoter polymorphism SNP309T→G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck,” Journal of Medical Genetics, vol. 42, no. 9, pp. 694–698, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. S. C. Girod, D. Cesarz, U. Fischer, and G. R. F. Krueger, “Detection of p53 and MDM2 protein expression in head and neck carcinogenesis,” Anticancer Research, vol. 15, no. 4, pp. 1453–1457, 1995. View at Google Scholar · View at Scopus
  16. G. L. Bond, W. Hu, E. E. Bond et al., “A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans,” Cell, vol. 119, no. 5, pp. 591–602, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Gasco and T. Crook, “p53 family members and chemoresistance in cancer: what we know and what we need to know,” Drug Resistance Updates, vol. 6, no. 6, pp. 323–328, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. F. Toledo and G. M. Wahl, “Regulating the p53 pathway: in vitro hypotheses, in vivo veritas,” Nature Reviews Cancer, vol. 6, no. 12, pp. 909–923, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Millon, D. Muller, I. Schultz et al., “Loss of MDM2 expression in human head and neck squamous cell carcinomas and clinical significance,” Oral Oncology, vol. 37, no. 8, pp. 620–631, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Sullivan, N. Syed, M. Gasco et al., “Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo,” Oncogene, vol. 23, no. 19, pp. 3328–3337, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Wan, W. Wu, Z. Yin, P. Guan, and B. Zhou, “MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis,” BMC Cancer, vol. 11, article 208, 2011. View at Publisher · View at Google Scholar
  22. H. Yu, Y.-J. Huang, Z. Liu et al., “Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck,” Molecular Carcinogenesis, vol. 50, no. 9, pp. 697–706, 2011. View at Publisher · View at Google Scholar
  23. G. L. Clayman, A. K. El-Naggar, S. M. Lippman et al., “Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma,” Journal of Clinical Oncology, vol. 16, no. 6, pp. 2221–2232, 1998. View at Google Scholar · View at Scopus
  24. M. Nakashima, S. Kondo, Y. Shimizu et al., “Impact of MDM2 single nucleotide polymorphism on tumor onset in head and neck squamous cell carcinoma,” Acta Oto-Laryngologica, vol. 128, no. 7, pp. 808–813, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Misra, M. Majumder, S. Bajaj, S. Ghosh, B. Roy, and S. Roychoudhury, “Polymorphisms at p53, p73, and MDM2 loci modulate the risk of tobacco associated leukoplakia and oral cancer,” Molecular Carcinogenesis, vol. 48, no. 9, pp. 790–800, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. H. F. Tu, H. W. Chen, S. Y. Kao, S. C. Lin, C. J. Liu, and K. W. Chang, “MDM2 SNP 309 and p 53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation,” Radiotherapy and Oncology, vol. 87, no. 2, pp. 243–252, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Hamid, Y. H. Yang, K. N. L. Peng et al., “MDM2 SNP309 does not confer an increased risk to oral squamous cell carcinoma but may modulate the age of disease onset,” Oral Oncology, vol. 45, no. 6, pp. 496–500, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. R. J. A. M. Michalides, N. M. J. Van Veelen, P. M. P. Kristel et al., “Overexpression of cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and neck,” Archives of Otolaryngology, vol. 123, no. 5, pp. 497–502, 1997. View at Google Scholar · View at Scopus
  29. M. L. Poeta, J. Manola, M. A. Goldwasser et al., “TP53 mutations and survival in squamous-cell carcinoma of the head and neck,” New England Journal of Medicine, vol. 357, no. 25, pp. 2552–2561, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. N. Vlatkoviä, A. El-Fert, T. Devling et al., “Loss of MTBP expression is associated with reduced survival in a biomarker-defined subset of patients with squamous cell carcinoma of the head and neck,” Cancer, vol. 117, no. 13, pp. 2939–2950, 2011. View at Publisher · View at Google Scholar
  31. F. Perrone, P. Bossi, B. Cortelazzi et al., “TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma,” Journal of Clinical Oncology, vol. 28, no. 5, pp. 761–766, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. P. L. Miliani de Marval and Y. Zhang, “The RP-Mdm2-p53 pathway and tumorigenesis,” Oncotarget, vol. 2, no. 3, pp. 234–238, 2011. View at Google Scholar
  33. A. Psyrri, E. Boutati, and S. Karageorgopoulou, “Human papillomavirus in head and neck cancers: biology, prognosis, hope of treatment, and vaccines,” Anti-Cancer Drugs, vol. 22, no. 7, pp. 586–590, 2011. View at Publisher · View at Google Scholar
  34. X. Chen, E. M. Sturgis, D. Lei, K. Dahlstrom, Q. Wei, and G. Li, “Human papillomavirus seropositivity synergizes with MDM2 variants to increase the risk of oral squamous cell carcinoma,” Cancer Research, vol. 70, no. 18, pp. 7199–7208, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. M. E. Sharafinski, R. L. Ferris, S. Ferrone, and J. R. Grandis, “Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck,” Head and Neck, vol. 32, no. 10, pp. 1412–1421, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. L. Farnebo, A. Jedlinski, A. Ansell et al., “Proteins and single nucleotide polymorphisms involved in apoptosis, growth control, and DNA repair predict cisplatin sensitivity in head and neck cancer cell lines,” International Journal of Molecular Medicine, vol. 24, no. 4, pp. 549–556, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. S. M. D. Prado, J. L. L. Cedrún, R. L. Rey et al., “Evaluation of COX-2, EGFR, and p53 as biomarkers of non-dysplastic oral leukoplakias,” Experimental and Molecular Pathology, vol. 89, no. 2, pp. 197–203, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Agarwal, M. Mathur, A. Srivastava, and R. Ralhan, “MDM2/p53 co-expression in oral premalignant and malignant lesions: potential prognostic implications,” Oral Oncology, vol. 35, no. 2, pp. 209–216, 1999. View at Publisher · View at Google Scholar · View at Scopus
  39. H. Shen and C. G. Maki, “Pharmacologic activation of p53 by small-molecule MDM2 antagonists,” Current Pharmaceutical Design, vol. 17, no. 6, pp. 560–568, 2011. View at Google Scholar
  40. W. Wang and W. S. El-Deiry, “Restoration of p53 to limit tumor growth,” Current Opinion in Oncology, vol. 20, no. 1, pp. 90–96, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. J. L. Roh, S. K. Kang, I. L. Minn, J. A. Califano, D. Sidransky, and W. M. Koch, “p53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma,” Oral Oncology, vol. 47, pp. 8–15, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. J. Nemunaitis, I. Ganly, F. Khuri et al., “Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial,” Cancer Research, vol. 60, no. 22, pp. 6359–6366, 2000. View at Google Scholar · View at Scopus
  43. J. R. Bischoff, D. H. Kirn, A. Williams et al., “An adenovirus mutant that replicates selectively in p53-deficient human tumor cells,” Science, vol. 274, no. 5286, pp. 373–376, 1996. View at Publisher · View at Google Scholar · View at Scopus